15 Aug, 2022
Consider joining our clinical research study for people who are immunocompromised with recently diagnosed, symptomatic COVID-19 may be eligible for extended PAXLOVID treatment as part of a new research study. You could participate in the study if: You are 12 years of age or older and weigh at least 40 kg(88 lbs). You have been recently diagnosed with COVID-19(<5 days) and currently have at least one symptom of COVID-19. You are to swallow tablets. You are Immunocompromised. There are other inclusion criteria that you must meet in order to participate. The study team member will help determine if this study is right for your family. Treatment and/or care related to the study is at no cost and you will be compensated for your time and participation. Participation is completely voluntary. By contacting us you are not committing yourself to take part in this study.